Compass Therapeutics (CMPX) vs Palisade Bio (PALI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Palisade Bio (PALI) has outperformed Compass Therapeutics (CMPX) over the past year, losing 60.6% versus a loss of 85.9%. Over five years, CMPX leads with a -78.6% price change compared with -100.0% for PALI. Palisade Bio is the larger company by market cap ($150.7 million vs $123.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | PALI |
|---|---|---|
| Share price | $0.6882 | $0.8399 |
| Market cap | $123.94M | $150.74M |
| 1-day change | +1.43% | -9.24% |
| YTD return | -87.18% | -64.26% |
| 1-year return | -85.87% | -60.57% |
| 5-year return | -78.63% | -99.95% |
| P/E ratio (TTM) | — | 0.91 |
| EPS (TTM) | $-0.46 | $0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $0 |
| Revenue growth (YoY) | -100.00% | — |
| Net income (latest FY) | $-66.49M | $-16.78M |
| 52-week high | $6.88 | $2.86 |
| 52-week low | $0.57 | $0.8381 |
| Distance from 52-week high | -90.00% | -70.63% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +664.31% | +935.84% |
| Average volume | 3.88M | 3.19M |
| Shares outstanding | 180.09M | 179.28M |
| Employees | 39 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PALI has outperformed CMPX by 25.3 percentage points over the past year.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
CMPX vs PALI FAQ
Which is bigger, Compass Therapeutics or Palisade Bio?
Palisade Bio (PALI) is larger, with a market capitalization of $150.74M compared with $123.94M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, CMPX or PALI?
PALI returned -60.57% over the past 12 months, compared with -85.87% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Palisade Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.